{'52WeekChange': 0.33950984,
 'SandP52WeekChange': None,
 'address1': '101 Montgomery Street',
 'address2': 'Suite 2000',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 49.38,
 'askSize': 800,
 'averageDailyVolume10Day': 57425,
 'averageVolume': 93947,
 'averageVolume10days': 57425,
 'beta': -0.278453,
 'beta3Year': None,
 'bid': 42.9,
 'bidSize': 800,
 'bookValue': 4.538,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 45.275,
 'dayLow': 43.09,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -31.204,
 'enterpriseToRevenue': 56.893,
 'enterpriseValue': 1518529152,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 48.241142,
 'fiftyTwoWeekHigh': 66.559,
 'fiftyTwoWeekLow': 28,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 10964259,
 'forwardEps': -2.78,
 'forwardPE': -15.809353,
 'fromCurrency': None,
 'fullTimeEmployees': 47,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.66331,
 'heldPercentInstitutions': 0.32455003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/eidostx.com',
 'longBusinessSummary': 'Eidos Therapeutics, Inc., a clinical stage '
                        'biopharmaceutical company, focuses on developing '
                        'drugs to treat diseases caused by transthyretin (TTR) '
                        'or amyloidosis (ATTR). It is developing AG10, which '
                        'is in phase 3 clinical trial, is an '
                        'orally-administered small molecule designed to '
                        'stabilize tetrameric TTR, thereby halting at its '
                        'outset the series of molecular events that give rise '
                        'to ATTR. The company was founded in 2013 and is '
                        'headquartered in San Francisco, California. Eidos '
                        'Therapeutics, Inc. is a subsidiary of BridgeBio '
                        'Pharma LLC.',
 'longName': 'Eidos Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1693714304,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_539024074',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -48926000,
 'nextFiscalYearEnd': 1640908800,
 'open': 43.99,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.65,
 'phone': '415 887 1471',
 'previousClose': 44.82,
 'priceHint': 2,
 'priceToBook': 9.684883,
 'priceToSalesTrailing12Months': 63.456383,
 'profitMargins': -1.8330499,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 45.275,
 'regularMarketDayLow': 43.09,
 'regularMarketOpen': 43.99,
 'regularMarketPreviousClose': 44.82,
 'regularMarketPrice': 43.99,
 'regularMarketVolume': 62091,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 38537300,
 'sharesPercentSharesOut': 0.0509,
 'sharesShort': 1960050,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1936209,
 'shortName': 'Eidos Therapeutics, Inc.',
 'shortPercentOfFloat': 0.17860001,
 'shortRatio': 17.22,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'EIDX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.319,
 'twoHundredDayAverage': 48.43554,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '1de6feb0-b129-341f-a32d-aeb0017eb28c',
 'volume': 62091,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.eidostx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94104'}